Stemedica's Technology for Spinal Cord Injury Shows Early Success

Written by Laura Dyrda | November 14, 2011 | Print  |
Stemedica Cell Technologies, a company focused on allogenic stem cell manufacturing, recently announced that its technology has been successful in treating spinal cord injury in rodent models, according to a Stemedica news release. Ivan Cheng, MD, assistant professor of orthopedic surgery at Stanford University School of Medicine, conducted the research using Stemedica's technology. During the study, he injected 24 rats with either Stemedica's ischemic tolerant human neural tem cells adjacent to the injury site or an intrathecal injection of neural stem cells distal to the injury site. Control subjects received a control media alone either local or distal to the injury site.

After following the rats for six weeks, Dr. Cheng found the acute transplantation of neural stem cells into the rat's injured spinal cord led to a significant recovery. The recovery occurred in subjects that received both local and distal injections.

The company is currently preparing an investigational new drug application for submission to the FDA and plans to launch human clinical trials during the first quarter of 2012.

Related Articles on Spine Surgery:

Cost-Effective Spine Surgery: 8 Things to Know

Study: ACDF, Cervical Arthroplasty Proven Beneficial for Cervical Disease Patients

Neuropathy or Radiculopathy: 4 Points on Differentiating the Diagnosis

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months